John Glasspool

Member of the Board Emerging Companies Section Governing Board

2022 - Current

Venture Partner

2018

Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.

Board Member

2019

Relmada (Nasdaq: $RLMD) is a clinical-stage company developing novel therapies for the treatment of CNS diseases.

Senior Advisor

2016

Advisor/Contributor on key initiatives, including financing/reimbursement models, policy recommendations for durable therapies, and Efficacy to Effectiveness (E2E) strategies.

CEO and President

2019 - 2024

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing innovative therapies for high-risk cardiovascular patients. The company’s lead program is abelacimab (MAA868), an antibody exhibiting dual inhibition of coagulation Factor XI and its activated form XIa. Early clinical trials indicate abelacimab has the potential to attenuate pathological thrombosis with minimal impact on hemostasis, thereby preventing or treating a variety of thrombotic disorders with lowered bleeding risk. Abelacimab’s anticipated monthly dosing combined with the potential for greater effectiveness and lowered bleeding profile are expected to provide major advantages over existing standards of care and allow greater numbers of people to be treated.

Board Member

2017 - 2023

DalCor is pioneering precision medicine for cardiovascular disease. The company is developing dalcetrapib, a unique cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile to maximize clinical benefit.

Consultant

2017 - 2018

Consulting to Roivant on commercial go-to-market activities, including operating, launch, and access plans.

EVP, Head of Corporate Strategy and Customer Operations

2015 - 2017

Member of Executive Team that led Baxalta through spin-off from Baxter Healthcare and subsequent merger agreement with Shire to form a Top 20 biopharma company. Championed external product development model and led Baxalta Ventures and Vitesse Biologics, along with more traditional business development and licensing and M&A, to create a conduit between innovation and commercialization.

VP, Head of Emerging Therapies and Market Development, Bioscience

2012 - 2015

Built oncology franchise from the ground up with three in-licenses agreements and development of an internal commercial team. Architect of commercial infrastructure for $12 billion business built around the changing needs of multiple stakeholders – patients, physicians, providers, payers, and policymakers (P5) – establishing a comprehensive approach to the successful launch of new drugs.

Head Region Europe - Vaccines & Diagnostic

2009 - 2012

Member of Executive Committee for division. Region head with revenue of more than $500 million and 275 people. Prepared for the commercial introduction of the first vaccine for meningitis B, including national recommendations. Collaborated with German health authorities to ensure competition in TBE vaccines after introduction of the AMNOG process. Partnered with DG Sanco on joint procurement agreements for European Union for potential pandemic threats.

Global Head Pharma Commercial Operations, Pricing and Market Access

2008 - 2009

Responsible for all Pharma product value proposition and process unit in global marketing and sales, analytics, and market research. Strengthened access process through introduction of iMAP (integrated market access plan) and risk-sharing schemes.

Head of Cardiovascular & Metabolism Franchise

2004 - 2008

Managed products from proof-of-concept to loss-of-exclusivity for business with sales of $6+ billion and 50 people. Grew CVM franchise sales from $4.9 billion to $6.7 billion over a three-year period. Managed multiple product launches.

Head of Neuroscience Franchise

2003 - 2004

Managed all stages of development for neuroscience products. Created study program and gained approval for first treatment for Parkinson’s dementia, despite FDA not initially accepting condition as a unique form of dementia.

Head of Marketing NS

2002 - 2003

Head of Marketing Neurology

2002 - 2003

Managed global marketing and sales for broad neurology portfolio, including epilepsy, Alzheimer’s, and Parkinson’s.